Schizophrenia spectrum disorders (SSDs) are complex syndromes involving psychopathological, cognitive, and also motor symptoms as core features. A better understanding of how these symptoms mutually impact each other could translate into diagnostic, prognostic, and, eventually, treatment advancements. The present study aimed to: (1) estimate a network model of psychopathological, cognitive, and motor symptoms in SSD; (2) detect communities and explore the connectivity and relative importance of variables within the network; and (3) explore differences in subsample networks according to remission status. A sample of 1007 patients from a multisite cohort study was included in the analysis. We estimated a network of 43 nodes, including all the items from the Positive and Negative Syndrome Scale, a cognitive assessment battery and clinical ratings of extrapyramidal symptoms. Methodologies specific to network analysis were employed to address the study's aims. The estimated network for the total sample was densely interconnected and organized into 7 communities. Nodes related to insight, abstraction capacity, attention, and suspiciousness were the main bridges between network communities. The estimated network for the subgroup of patients in remission showed a sparser density and a different structure compared to the network of nonremitted patients. In conclusion, the present study conveys a detailed characterization of the interrelations between a set of core clinical elements of SSD. These results provide potential novel clues for clinical assessment and intervention.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8266645PMC
http://dx.doi.org/10.1093/schbul/sbab002DOI Listing

Publication Analysis

Top Keywords

psychopathological cognitive
12
cognitive motor
12
motor symptoms
12
estimated network
12
network
9
schizophrenia spectrum
8
spectrum disorders
8
symptoms
5
network psychopathological
4
cognitive
4

Similar Publications

Background: Borderline Personality Disorder (BPD) is a prevalent psychopathological condition, affecting 0.7-2.7% of the general population.

View Article and Find Full Text PDF

Transdiagnostic conceptualization of schizophrenia and autism spectrum disorder. An integrative framework of minimal self disturbance.

Neuropsychopharmacol Hung

December 2024

Pszichiátriai és Pszichoterápiás Klinika, Semmelweis Egyetem, Budapest.

Article Synopsis
  • The study suggests that autism spectrum disorder and schizophrenia may share overlapping features, particularly regarding minimal self-experience, characterized by altered body ownership and agency.
  • A literature review highlighted tools used to assess self-experience in both disorders, revealing that minimal self-disturbances are significant in both, though they manifest differently.
  • The findings indicate that these disorders might be part of a shared psychopathological continuum, with common neural mechanisms contributing to self-disturbances across the conditions.
View Article and Find Full Text PDF

The present study aimed to investigate the causal relationships among cognitive impairment, psychopathology, and real-life functioning in a large sample of people with schizophrenia, using a data-driven causal discovery procedure based on partial ancestral graphs (PAGs). This method may provide additional insights for the identification of potential therapeutic targets to promote recovery in people with chronic schizophrenia. State-of-the-art instruments were used to assess the study variables.

View Article and Find Full Text PDF

Background And Hypothesis: Respective abnormal structural connectivity (SC) and functional connectivity (FC) have been reported in individuals with schizophrenia. However, transmodal associations between SC and FC following antipsychotic treatment, especially in female schizophrenia, remain unclear. We hypothesized that increased SC-FC coupling may be found in female schizophrenia, and could be normalized after antipsychotic treatment.

View Article and Find Full Text PDF

An exploratory study of the safety profile and neurocognitive function after single doses of mitragynine in humans.

Psychopharmacology (Berl)

December 2024

Department of Neuropsychology and Psychopharmacology, Faculty of Psychology and Neuroscience, Maastricht University, P.O. Box 616, Maastricht, 6200 MD, The Netherlands.

Rationale: Despite the growing scientific interest on mitragynine, the primary alkaloid in kratom (Mitragyna Speciosa), there is a lack of clinical trials in humans.

Objectives: This phase 1 study aimed to evaluate mitragynine's safety profile and acute effects on subjective drug experience, neurocognition, and pain tolerance.

Methods: A placebo-controlled, single-blind, within-subjects study was conducted in two parts.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!